May 5, 2025 8:09am
Keep portfolio moves simple, bearing in mind Occam’s Razor … “A principle that in explaining a thing no more assumptions should be made than are necessary”
When trying to understand “our universe” of cell and gene therapy, some timing moves are irrelevant although many can bring the best results
Earnings: BLFS and NTLA 5/8
No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief
Never leave an investor uninformed!
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!
Friday’s night’s … RegMed Investors (RMi) Closing Bell: Rippen with this a.m.’s answer, not econs today after past ticks exacerbated stocks … https://www.regmedinvestors.com/articles/13904
RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN), The latest, WHAT happens to OTCQB: HRGN if the White House and the new head of the SEC starts to "DELIST" Chinese companies??? … Newest happening, public accountants walk … https://www.regmedinvestors.com/articles/13812
Monday: The pre-open Dow futures are DOWN -0.67% or (-276 points), the S&P futures are DOWN -0.88% or (-50 points) and the Nasdaq futures are DOWN -1.07% or (-216 points)
- U.S. stock futures dropped Monday as Wall Street comes off a winning week,
- European markets were mixed,
- Asia Pacific markets were mixed
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
Last week:
Friday: The Dow closed UP +564.47 points or +1.39%, the S&P closed UP +82.53 points or +1.47% while the Nasdaq closed UP +266.99 points or +1.51%
Thursday: The Dow closed UP +83.42 points or +0.21%, the S&P closed UP +35.05 points or +0.63% while the Nasdaq closed UP +264.40 points or +1.52%
Wednesday: The Dow closed UP +141.74 points or +0.35%, the S&P closed UP +8.23 points or +0.15% while the Nasdaq closed DOWN -14.98 points or -0.09%
Tuesday: The Dow closed UP +300.03 points or +0.75%, the S&P closed UP +32.04 points or +0.58% while the Nasdaq closed UP +95.18 points or +0.55%
Monday: The Dow closed UP +114.09 points or +0.28%, the S&P closed UP +3.54 points or +0.06% while the Nasdaq closed DOWN -16.81 points or -0.10%
Economic Data Docket: S&P final U.S. services PM and ISM services
Q2 – May – 1 negative and 1 positive close
- Q2 - April – 10 negative and 11 positive closes
Q1/25
- March, 10 positive and 11 negative closes
- February – 12 holiday, 11 negative and 7 positive closes
- January - 2 holidays, 1 market close, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
- Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the … econs, it is still a mix of ups, downs and just uncertainty
Although: some indications of a frothy sector for today, Monday …
Alnylam Pharmaceuticals (ALNY) closed up +$4.26 with a negative -$2.91 or -1.12% pre-open
Beam Therapeutics (BEAM) closed up +$0.41 with a negative -$0.40 or -1.98% pre-open
Blueprint Medicine (BPMC) closed up =$5.39 with a negative -$0.65 or -0.62% pre-open
CRISPR Therapeutics (CRSP) closed up +$0.52 with a negative -$0.19 or -0.50% pre-open
Ionis Pharmaceuticals (IONS) closed up +$1.07 with a negative -$0.03 or -0.09% pre-open
Vericel (VCEL) closed up +$1.03 with a negative -$0.34 or -0.87% pre-open
The BOTTOM LINE: Cell and gene Therapy sector equities stocks popped positive in the 2nd session after diving on the 1st session of May after finishing April to end in a positive close.
- Wild swings will continue
The last week of April and Q1; Tuesday and Monday closed negative …
- Last week, the cell and gene therapy sector dived on Friday after bounding on Thursday, Wednesday, Tuesday and Monday.
May ‘25: understand the “flow” of bad market and economic karma…
- 5/2 – Friday closed positive with 24 positive, 8 negative and 3 flats
- 5/1 – Thursday closed negative with 14 positive, 19 negative and 2 flats
Last 2 weeks of April:
- 4/30 - Wednesday closed positive with 23 positive, 10 negative and 2 flats
- 4/29 – Tuesday closed negative with 14 positive, 20 negative and 1 flat
- 4/28 - Monday closed negative with 15 positive, 19 negative and 2 flats
Brace ourself for more economics and their down trending affect?
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
